Discover the effects of celiac disease on the immune system in the body and what it means for those affected by it.

Abstract

Gluten-related disorders represent one of the most misunderstood and underdiagnosed areas in modern medicine. In this educational post, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, walk you through the key biological and immunological distinctions between celiac disease and non-celiac gluten sensitivity (NCGS)—two conditions too often lumped together in conventional clinical practice. Understanding these differences is not merely academic; it has profound, life-altering implications for every patient who walks through our doors.

We explore the physiological mechanisms of intestinal permeability, the role of zonulin and gliadin in breaking down the gut barrier, and the immune cascade that follows. We examine how tissue transglutaminase (TTG) becomes the target of a misdirected immune attack, why the intestinal villi are progressively destroyed in celiac disease, and how that destruction leads to systemic consequences including osteoporosis, neurological damage, cardiovascular compromise, and widespread nutrient malabsorption.

We also discuss the critically important concept of threshold dynamics — the “bucket model” of cumulative gut stress — which explains why so many patients do not develop overt symptoms until their forties or later, despite a lifetime of low-level immune priming.

Throughout this post, I present the latest evidence-based research to support these physiological explanations and connect each concept to a practical, integrative clinical framework. You will learn how our multidisciplinary team at Injury Medical Clinic PA in El Paso, Texas — led by me alongside Dr. Maria Guadalupe Cardenas, MD, Board-Certified Internist and Medical Director with over 40 years of clinical experience — uses a collaborative, whole-patient model that integrates chiropractic care, functional medicine, internal medicine oversight, personal injury rehabilitation, and nutritional medicine to address these complex immune-driven conditions comprehensively and compassionately.

Whether you are a patient trying to make sense of your diagnosis, a clinician looking to deepen your understanding, or someone who wants to know why gluten is making you feel so unwell, this post is written for you.

Meet the Clinical Team: Dr. Alex Jimenez and Dr. Maria Guadalupe Cardenas

Before diving into the science, I want to introduce the team behind this work, because the clinical philosophy that shapes everything I share here is rooted in collaborative, integrative, patient-centered care.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

I am Dr. Alex Jimenez, and I have spent decades working at the intersection of chiropractic medicine, functional medicine, advanced practice nursing, and integrative health. My training and certifications reflect a commitment to understanding the human body not as a collection of isolated systems but as a deeply interconnected whole. I hold credentials as a Doctor of Chiropractic (DC), an Advanced Practice Registered Nurse (APRN), a Family Nurse Practitioner Board-Certified (FNP-BC), a Certified Functional Medicine Practitioner (CFMP), an Institute for Functional Medicine Certified Practitioner (IFMCP), an Advanced Trauma Nurse (ATN), and a Certified Chiropractic Sports Therapist (CCST).

My clinical observations, case documentation, and patient education work are published and accessible at personalinjurydoctorgroup.com and through my professional profile on LinkedIn. I have devoted my career to bridging conventional medicine and evidence-based integrative approaches, and conditions like celiac disease and non-celiac gluten sensitivity represent exactly the kind of complex, systemic, multi-organ presentations that require that bridge.

Dr. Maria Guadalupe Cardenas, MD — Medical Director and Collaborative Physician

Working alongside me is Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933), a physician Board-Certified in Internal Medicine with over 40 years of clinical experience as a practicing internist. Dr. Cardenas serves as our Medical Director and Collaborative Physician at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, located in El Paso, Texas.

Dr. Cardenas brings extraordinary clinical wisdom to our practice. Internal medicine, by its very nature, requires a physician to think systemically — to look beyond a single chief complaint and consider how all the body’s organ systems interact. This is precisely the lens required to manage patients with gluten-related immune disorders, where the consequences of intestinal immune dysregulation ripple outward into the cardiovascular system, the nervous system, the skin, the endocrine system, and the musculoskeletal system.

Her role as Medical Director ensures every patient at our clinic receives medically sound, evidence-based oversight integrated seamlessly with the functional, rehabilitative, and chiropractic services we provide.

Our Multidisciplinary Model at Injury Medical Clinic PA

Injury Medical Clinic PA operates as a multidisciplinary integrative clinic, a model that is increasingly recognized in the peer-reviewed literature as the most effective approach for managing complex, chronic, and injury-related conditions (Haldeman & Dagenais, 2008). In our clinic:

• Cardenas provides internal medicine evaluation, medical direction, and oversight for patients with complex systemic presentations, including those with autoimmune conditions, metabolic disorders, and gluten-related immune diseases.
• I, Dr. Jimenez, provide chiropractic care, functional medicine assessment, nutritional medicine guidance, and integrative health coaching.
• Our team also incorporates rehabilitation services, personal injury care, and advanced diagnostic evaluation, allowing us to meet patients wherever they are in their health journey.

This collaborative structure is not incidental — it is intentional. The science of conditions like celiac disease demands it. When a patient’s immune system attacks its own intestinal villi, the consequences include musculoskeletal deterioration from nutrient malabsorption, neurological symptoms that may present as peripheral neuropathy or ataxia, cardiovascular risk driven by systemic inflammation, and dermatological manifestations that confuse dermatologists not trained to look upstream at the gut. Managing these patients well requires a team.

Celiac Disease and Non-Celiac Gluten Sensitivity Are Not the Same Condition

One of the most important clinical clarifications I make in my practice is this: celiac disease and non-celiac gluten sensitivity (NCGS) are fundamentally different conditions, driven by different immunological mechanisms, producing different degrees of tissue damage, and requiring somewhat different clinical management strategies. Yet in everyday medical practice — and I say this not to criticize but to inform — these two conditions are routinely conflated, and patients often receive the same oversimplified advice regardless of which condition they actually have.

Let me be very clear: this matters enormously. The distinction determines whether you are dealing with a permanent, adaptive immune-mediated autoimmune process or a reversible, innate immune-driven sensitivity reaction. These are not the same, and treating them as such does a disservice to patients.

Celiac Disease: A Permanent Adaptive Immune Response

Celiac disease is a chronic autoimmune disorder in which the ingestion of gluten — a composite of storage proteins found primarily in wheat, barley, and rye — triggers an adaptive immune response that is directed against the body’s own intestinal tissue (Fasano & Catassi, 2012). The key word here is adaptive. The adaptive immune system is the part of your immune defense that learns, remembers, and produces highly specific weapons — namely, antibodies — against particular targets.

In celiac disease, the immune system generates specific IgG and IgA antibodies directed not only against gluten proteins but also against the body’s own enzyme, tissue transglutaminase (TTG), and against the intestinal cells themselves. This is the hallmark of autoimmunity: the immune system has lost the ability to distinguish between “self” and “non-self” and is actively attacking the body’s own tissues.

The critical word that defines celiac disease clinically is permanent. Once the adaptive immune response against gluten-related antigens has been established in a genetically susceptible individual, it does not go away. The immune system has been trained. It has memory. Every subsequent exposure to gluten will re-trigger this attack. This is why celiac disease requires lifelong, strict gluten elimination — not management, not reduction, not moderation. Elimination.

The genetic component of celiac disease is well-established. Approximately 95% of celiac patients carry the HLA-DQ2 haplotype, and most of the remaining 5% carry HLA-DQ8 (Lundin & Wijmenga, 2015). These genetic variants encode particular shapes of the antigen-presenting molecules on immune cells, shapes that happen to bind gluten-derived peptides with unusual affinity and efficiency, presenting them to T cells in a way that drives a powerful and destructive immune response.

But genetics alone do not determine destiny. Many individuals carry HLA-DQ2 or HLA-DQ8 without ever developing celiac disease — which brings us to the concept of threshold dynamics, which I will explain in detail later in this post.

Non-Celiac Gluten Sensitivity: A Reversible Innate Immune Response

Non-celiac gluten sensitivity (NCGS) is a fundamentally different condition. Rather than involving the adaptive immune system’s antibody production and immune memory, NCGS is driven primarily by the innate immune system—the older, faster, less specific arm of immune defense that responds to threats through pattern recognition rather than antibody production (Sapone et al., 2012).

In NCGS, the body reacts to the structural features of wheat proteins — including but not limited to gliadin, amylase trypsin inhibitors (ATIs), and fructans (a type of fermentable carbohydrate) — through innate immune activation. This causes gut inflammation, intestinal irritation, and systemic symptoms, but without the IgG/IgA antibody-mediated attack on the intestinal villi that characterizes celiac disease.

The clinical consequence of this distinction is enormous: in NCGS, the intestinal villi are not being destroyed. The small intestinal architecture is essentially preserved, even while the patient feels genuinely terrible. NCGS can cause bloating, diarrhea, brain fog, fatigue, joint pain, skin rashes, and many other symptoms—and it does so through irritation rather than immune destruction.

Because NCGS does not involve the same adaptive immune mechanism as celiac disease, it is reversible in most cases. With appropriate gut-healing protocols, microbiome restoration, removal of triggering foods, and reduced inflammatory load, patients with NCGS can often recover full tolerance to gluten or, at minimum, dramatically reduce symptom severity. This is a message of genuine hope — and it stands in stark contrast to the permanent nature of celiac disease.

It is also worth noting that NCGS is far more prevalent than celiac disease. While celiac disease affects about 1% of the global population (Rubio-Tapia et al., 2012), estimates for NCGS range from 0.5% to as high as 1%. However, definitive epidemiological data remain difficult to establish because NCGS lacks a reliable serological biomarker (Catassi et al., 2015).

The Immunological Architecture of Celiac Disease: How the Adaptive Immune Response Destroys Intestinal Tissue

To truly understand why celiac disease is so damaging and why its management demands such vigilance, we need to explore the immunological machinery at work in the small intestine. This is not abstract biology — it is the story of how your immune system, trying to protect you, ends up systematically dismantling the very tissues it was designed to defend.

The Small Intestine as a Nutrient Filter: Anatomy and Function

The small intestine is arguably the most architecturally sophisticated organ in the human body for its functional purpose. Stretching approximately 6 to 7 meters in length in adults, its luminal surface is covered by intestinal villi — tiny, finger-like projections of mucosa that extend into the lumen of the gut. Each villus is covered by enterocytes—absorptive epithelial cells—that have projections on their apical surfaces called microvilli, which collectively form the brush border.

This architectural arrangement is the body’s engineering solution to a very specific problem: how to maximize the surface area available for nutrient absorption within a tube of limited length. The combined effect of villi and microvilli increases the absorptive surface area of the small intestine to approximately 200 square meters — roughly the size of a tennis court — all folded within a body cavity (Kiela & Ghishan, 2016).

Every essential nutrient — vitamins, minerals, amino acids, fatty acids, glucose — must pass through this single-cell-thick absorptive layer to enter the bloodstream and nourish every organ in the body. Clinically, I describe the small intestine as a “nutrient filter, one cell layer thick.” That single layer of cells, the intestinal epithelium, is the only barrier between the contents of the gut and the bloodstream. A specialized molecular glue holds it together: tight junctions.

Tight Junctions: The Molecular Glue of Gut Integrity

Tight junctions are complex protein assemblies located between adjacent intestinal epithelial cells. They function as selective paracellular barriers — meaning they control what passes between cells rather than through them. A healthy, intact tight junction network ensures that only properly absorbed nutrients, transported through enterocytes’ cellular machinery, pass into the bloodstream. As long as tight junctions remain intact, they exclude undigested food particles, bacteria, bacterial toxins, and foreign proteins from the circulation (Turner, 2009).

Tight junctions contain proteins such as occludin, claudins, and zonula occludens (ZO) proteins. These proteins form a dynamic seal that can be modulated — tightened or loosened — in response to physiological and pathological signals. In health, this modulation is a normal part of intestinal physiology. In celiac disease, this modulation becomes catastrophic.

Gliadin, Zonulin, and the Opening of the Gut Barrier

Here is where the story of celiac disease begins at the molecular level. When a genetically susceptible individual consumes gluten, the gliadin fraction of gluten — a specific group of proteins found in wheat — enters the intestinal lumen. In healthy individuals, gliadin is digested relatively efficiently. But in susceptible individuals, certain gliadin peptides resist complete digestion and remain intact long enough to interact with intestinal epithelial cells.

When gliadin fragments interact with intestinal epithelial cells, they trigger the upregulation and release of zonulin — a protein first described by Dr. Alessio Fasano and his research team, now recognized as the primary physiological regulator of intestinal tight junction permeability (Fasano, 2012). Zonulin binds to receptors on epithelial cells and triggers a signaling cascade that causes tight junction proteins to disassemble and retract, opening gaps between cells.

The consequence is what is clinically known as increased intestinal permeability, or in more accessible language, “leaky gut.” Once tight junctions are disrupted:

• Undigested food proteins, including gliadin itself, can pass directly into the subepithelial space and bloodstream.
• Bacterial cell wall components (lipopolysaccharides, or LPS), normally confined to the gut lumen, can translocate into systemic circulation.
• Microbial toxins and other luminal antigens gain access to the immune surveillance network of the lamina propria — the immune-rich connective tissue layer just beneath the epithelium.

This is the biological moment when a local gut problem becomes a systemic inflammatory event.

Tissue Transglutaminase and the Creation of the Autoimmune Target

Once gliadin peptides have breached the intestinal epithelial barrier and entered the subepithelial tissue, they encounter an enzyme called tissue transglutaminase (TTG) — specifically transglutaminase 2 (TG2), the most abundant transglutaminase in the body, expressed in endothelial cells, smooth muscle cells, intestinal epithelial cells, and many other tissues.

TTG is normally a repair enzyme. Its job includes cross-linking proteins to stabilize the extracellular matrix, participating in wound healing, and modifying proteins in various tissues. But when TTG encounters gliadin peptides, it performs a chemical modification called deamidation — converting specific glutamine residues in gliadin to glutamic acid residues. This seemingly small chemical change dramatically increases the affinity of gliadin peptides for HLA-DQ2 and HLA-DQ8 molecules on the surface of antigen-presenting cells (Sollid et al., 2012).

The result is that TTG-modified gliadin peptides are now presented with exceptional efficiency to CD4+ T helper cells in the lamina propria. These T cells recognize the modified gliadin as a foreign threat and mount an aggressive immune response. But here is the twist that defines celiac disease as an autoimmune rather than merely an inflammatory condition:

The immune response generates antibodies not only against gliadin itself but also against tissue transglutaminase — the body’s own enzyme. In trying to destroy the foreign protein, the immune system produces IgG and IgA antibodies against TTG-gliadin complexes. Because TTG is so widely distributed in the body’s own tissues, these antibodies effectively become weapons against the body itself.

Where TTG Is Found: Endothelium, Skin, and Intestinal Villi

This point deserves emphasis because it explains the breathtaking systemic scope of celiac disease pathology. Tissue transglutaminase is not confined to the intestine. It is expressed in:

• Intestinal villi and enterocytes — explaining the destruction of absorptive surface area and the resulting malabsorption
• Endothelial cells lining blood vessels throughout the body — explaining the cardiovascular complications of untreated celiac disease, including increased risk of coronary artery disease and cardiomyopathy (Emilsson et al., 2015)
• Skin — specifically in the dermal papillae of the dermis — explaining the dermatological manifestation of celiac disease known as dermatitis herpetiformis
• Neural tissue — contributing to gluten ataxia and peripheral neuropathy, neurological conditions driven by antibody-mediated damage to cerebellar and peripheral neural structures (Hadjivassiliou et al., 2010)

This is not a gut disease. It is a systemic autoimmune disease that happens to be triggered by gluten, and that uses the gut as its primary battlefield, but wages war across multiple organ systems simultaneously.

Villous Atrophy: The Central Pathological Lesion of Celiac Disease

The most well-characterized pathological consequence of celiac autoimmunity is villous atrophy — the progressive flattening and eventual destruction of the intestinal villi. As the immune attack on TTG-expressing cells intensifies, the immune system dismantles the delicate villous architecture. A flattened, inflamed mucosa replaces the finger-like projections that maximize absorptive surface area, with marked crypt hyperplasia (overgrowth of the intestinal crypts as the intestine attempts to compensate) and increased intraepithelial lymphocytes.

The histological grading of intestinal damage in celiac disease is standardized using the Marsh classification (or the modified Marsh-Oberhuber classification):

• Marsh 0: Normal mucosa
• Marsh 1: Increased intraepithelial lymphocytes (>25 per 100 enterocytes) with normal villi
• Marsh 2: Increased intraepithelial lymphocytes with crypt hyperplasia, normal villi
• Marsh 3a: Mild villous atrophy
• Marsh 3b: Moderate villous atrophy
• Marsh 3c: Complete villous atrophy (total flattening)

In patients with Marsh 3c lesions, the small intestine’s absorptive surface area can be reduced by more than 80% compared with a healthy intestine (Wahab et al., 2002). The consequences for nutrient absorption are catastrophic.

The Systemic Consequences of Untreated Celiac Disease

When the immune system actively destroys intestinal villi and severely compromises absorptive capacity, the effects extend beyond gastrointestinal symptoms. I want to walk through each major systemic consequence because understanding these helps patients appreciate the gravity of continuing to consume gluten when celiac disease is present.

Osteoporosis and Metabolic Bone Disease

Calcium and vitamin D are absorbed primarily in the duodenum and proximal jejunum — the very regions of the small intestine that are most severely damaged in celiac disease. When villous atrophy is present, calcium absorption is dramatically impaired. The body compensates by increasing parathyroid hormone (PTH) secretion, which mobilizes calcium from bone to maintain serum calcium levels within the narrow range required for cardiac and neuromuscular function.

The long-term consequence of this calcium mobilization is secondary hyperparathyroidism and progressive osteopenia progressing to osteoporosis. Studies have consistently shown that patients with untreated celiac disease have significantly lower bone mineral density (BMD) than healthy controls, and their fracture risk is substantially elevated — with some data suggesting a 40% increased risk of hip fracture in celiac patients compared to the general population (Olmos et al., 2008).

Vitamin D deficiency, also resulting from impaired absorption, compounds this problem. Vitamin D is essential not only for calcium absorption but also for immune regulation, neuromuscular function, and cardiovascular health—all of which matter for celiac patients. Magnesium malabsorption further amplifies bone loss, as magnesium is a required cofactor for vitamin D activation and PTH function.

In our integrative practice, patients presenting with unexplained osteoporosis — particularly in younger individuals who would not typically be considered at risk — are always evaluated for underlying celiac disease as a potential contributing factor, precisely because this presentation is so common and so frequently missed.

Neurological Damage: Gluten Ataxia and Peripheral Neuropathy

Perhaps the most alarming systemic manifestation of celiac disease is neurological damage. Dr. Marios Hadjivassiliou and colleagues at the Royal Hallamshire Hospital in Sheffield, UK, introduced the term gluten ataxia to describe a progressive cerebellar ataxia caused by gluten-driven, immune-mediated damage to the cerebellum (Hadjivassiliou et al., 2003).

The mechanism involves anti-TTG antibodies cross-reacting with Purkinje cells in the cerebellum—highly specialized neurons that coordinate movement and balance. As the immune attack damages or destroys these neurons, patients develop progressive imbalance, unsteady gait, and loss of coordination. Unlike many other forms of ataxia, gluten ataxia can be halted and partially reversed with strict gluten elimination, provided the diagnosis is made before too much irreversible neuronal loss has occurred.

Peripheral neuropathy—manifesting as numbness, tingling, burning sensations, or weakness in the extremities—is another well-documented neurological complication of celiac disease, occurring in about 8% of all peripheral neuropathy cases of unknown origin (Hadjivassiliou et al., 2010). Mechanisms include both direct antibody-mediated neural damage and the effects of B vitamin deficiencies—particularly thiamine (B1), pyridoxine (B6), cobalamin (B12), and folate—all of which depend on intact small intestinal absorption and are essential for normal nerve function.

From a chiropractic and integrative medicine perspective, these neurological presentations are clinically significant. Patients who present with unexplained neuropathy, balance disorders, or progressive neurological decline without a clear conventional explanation deserve evaluation for gluten-related immune pathology. I have seen this presentation in my clinical work, and identifying and addressing the underlying gluten mechanism can be transformative.

Cardiovascular Damage: The Endothelial Connection

The cardiovascular consequences of untreated celiac disease are less widely known but are documented in the peer-reviewed literature with increasing clarity. The mechanism connects directly to the tissue distribution of TTG that we discussed earlier.

Endothelial cells — the cells lining the interior of blood vessels — express TTG on their surfaces. Anti-TTG antibodies generated in response to gluten exposure can therefore bind to and damage the vascular endothelium. This endothelial damage initiates a cascade of pro-inflammatory and pro-thrombotic events: increased adhesion-molecule expression, impaired nitric oxide production, platelet aggregation, and endothelial dysfunction—the foundational pathological process underlying atherosclerosis and cardiovascular disease (Emilsson et al., 2015).

Studies have also shown that celiac patients have a significantly elevated risk of cardiomyopathy — particularly dilated cardiomyopathy — which may be mediated by anti-TTG antibodies targeting cardiac muscle tissue expressing TG3 (a cardiac isoform of transglutaminase) (Frustaci et al., 2002). Additionally, the systemic inflammation from ongoing celiac autoimmunity elevates C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-?)—all recognized markers of cardiovascular risk.

Nutrient malabsorption also contributes to cardiovascular risk in celiac disease: folate and B12 deficiencies are associated with elevated homocysteine levels, a well-established independent risk factor for cardiovascular disease (Refsum et al., 2004). Iron deficiency anemia, common in celiac disease due to impaired duodenal iron absorption, places additional stress on the cardiovascular system.

Nutrient Malabsorption: A Cascade of Systemic Deficiencies

Villous atrophy produces global nutrient malabsorption that is both comprehensive and clinically devastating. The affected nutrients and their clinical consequences include:

• Iron: Absorbed primarily in the duodenum. Deficiency causes iron-deficiency anemia, fatigue, cognitive impairment, and immune compromise. Iron-deficiency anemia is frequently the presenting symptom of celiac disease, particularly in women of reproductive age.
• Calcium and Vitamin D: As discussed, deficiency causes osteoporosis and contributes to neuromuscular dysfunction and immune dysregulation.
• Folate (Vitamin B9): Absorbed in the proximal jejunum. Deficiency causes megaloblastic anemia, neural tube defects in pregnancy, elevated homocysteine, and impaired DNA synthesis.
• Vitamin B12 (Cobalamin): Deficiency causes pernicious anemia, peripheral neuropathy, cognitive decline, and psychiatric symptoms.
• Zinc: Essential for immune function, wound healing, and neurotransmitter synthesis. Deficiency contributes to immune compromise, poor wound healing, hair loss, and impaired taste and smell.
• Magnesium: Required for over 300 enzymatic reactions in the body, including ATP production, protein synthesis, and neuromuscular function. Deficiency contributes to muscle cramps, cardiac arrhythmias, anxiety, and insulin resistance.
• Fat-soluble vitamins (A, E, K): Malabsorbed due to impaired fat digestion secondary to intestinal damage. Deficiencies contribute to night blindness (vitamin A), peripheral neuropathy (vitamin E), and coagulation disorders (vitamin K).
• Essential amino acids: Protein absorption is impaired, contributing to muscle wasting, impaired repair, and reduced synthesis of neurotransmitters and hormones.

The clinical picture that emerges from this global malabsorption syndrome is one of accelerated multi-system deterioration. This patient appears to age faster than their chronological years, with an immune system that is perpetually exhausted, bones that are thinning, a nervous system under attack, and a cardiovascular system that is silently accumulating inflammatory damage. All from eating bread.

This is why I tell my patients: there is no supplement, no tea, and no therapeutic hack that allows you to continue eating gluten if you have celiac disease. The biological mechanism does not respond to workarounds. The only intervention that stops the immune attack is completely removing the trigger.

The Immunology of Non-Celiac Gluten Sensitivity: Innate Immune Activation Without Adaptive Autoimmunity

Having established the devastating scope of celiac disease immunopathology, let us now turn to non-celiac gluten sensitivity (NCGS) and understand it on its own terms — not as a lesser version of celiac disease, but as a distinct pathophysiological entity with its own mechanisms, manifestations, and management implications.

The Innate Immune System: First Responders Without Memory

The innate immune system is the body’s first line of defense — present from birth, non-specific, and fast-acting. Unlike the adaptive immune system, which requires days to mount a response and then remembers specific antigens for decades, the innate immune system responds within minutes to hours to molecular patterns associated with danger or infection.

The innate immune response relies on pattern recognition receptors (PRRs) — including Toll-like receptors (TLRs), NOD-like receptors, and others — that recognize conserved structural patterns called pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). When these receptors are activated, they trigger inflammatory responses by producing cytokines, chemokines, and reactive oxygen species.

In NCGS, specific components of wheat — including gliadin, amylase trypsin inhibitors (ATIs), and fructans — activate innate immune receptors in the intestinal mucosa, particularly TLR2 and TLR4, driving an innate inflammatory response (Junker et al., 2012). This response is real, biologically measurable, and produces genuine, often severe symptoms.

The Role of Amylase Trypsin Inhibitors in NCGS

While gliadin has historically received the most attention in discussions of gluten sensitivity, growing research highlights the significant role of amylase trypsin inhibitors (ATIs) — a family of small, compact proteins found in wheat that constitute only 2-4% of total wheat protein but appear to be potent activators of innate immune signaling.

ATIs activate TLR4 receptors on intestinal epithelial cells, macrophages, and dendritic cells, triggering the production of pro-inflammatory cytokines including IL-1, IL-6, IL-8, and TNF-?. (Junker et al., 2012). This innate immune activation can occur even without increased intestinal permeability, meaning some patients with NCGS may experience significant systemic inflammatory symptoms without the degree of leaky gut seen in celiac disease.

ATIs are also highly resistant to digestive enzymes and heat, meaning they survive cooking and digestion relatively intact, maintaining their receptor-activating capacity throughout transit to the intestinal mucosa.

The Role of Fructans: FODMAP Overlap with NCGS

Fructans are a type of FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) — short-chain carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by gut bacteria in the colon, producing gas, bloating, osmotic diarrhea, and abdominal discomfort.

A landmark study published in Gastroenterology by Skodje et al. (2018) demonstrated that in self-reported non-celiac gluten sensitivity, fructans rather than gluten were the primary driver of gastrointestinal symptoms in a double-masked crossover trial. This finding has important clinical implications: it suggests that a significant subset of patients who believe they are reacting to gluten may actually be reacting primarily to the wheat’s fructan content, and that a low-FODMAP approach rather than strict gluten elimination may be sufficient to manage their symptoms.

This is precisely the kind of nuance that requires careful clinical evaluation—the kind of evaluation that cannot happen in a rushed 10-minute appointment, and that benefits enormously from the integrative approach we employ at Injury Medical Clinic PA.

Why NCGS Symptoms Are Real Despite the Absence of Villous Atrophy

One of the most important things I communicate to patients with NCGS is this: the fact that your villi are not being destroyed does not mean your symptoms are not real. The innate immune response activated by wheat proteins in NCGS produces:

• Increased intestinal permeability (elevated zonulin in a subset of patients, though not universally)
• Mast cell activation — with degranulation releasing histamine, prostaglandins, and other inflammatory mediators that drive abdominal pain, diarrhea, and systemic symptoms
• Activation of enteric nervous system neurons — contributing to visceral hypersensitivity and altered gut motility
• Systemic cytokine release — causing the fatigue, brain fog, joint pain, and general malaise that NCGS patients frequently report

What NCGS does not produce — or produces only transiently and at a much lower level than celiac disease — is the progressive, antibody-mediated destruction of villous architecture. This distinction has a crucially positive implication: in most cases, NCGS is reversible. With appropriate treatment, the gut can heal, innate immune activation can resolve, and normal wheat tolerance may ultimately return.

Eating Right to Feel Better-Video

The Critical Importance of Proper Diagnostic Testing: The TTG IgA Test and the Gluten Challenge Requirement

I cannot overstate how many patients come to my practice having had incorrect or inconclusive testing for celiac disease. Understanding the diagnostic process—and why certain pre-test conditions matter so much — can be the difference between a meaningful diagnosis and a dangerously false-negative result.

The TTG IgA Test: Gold Standard Serology for Celiac Disease

The current gold-standard serological test for celiac disease is the anti-tissue transglutaminase IgA antibody (TTG-IgA) test, which measures IgA antibodies directed against TTG in the blood. This test has sensitivity and specificity exceeding 95% for celiac disease in patients actively consuming gluten (Husby et al., 2020).

In clinical practice, TTG-IgA is typically accompanied by measurement of total serum IgA to rule out selective IgA deficiency — a condition affecting approximately 2-3% of celiac patients, in whom TTG-IgA levels would be falsely low because the patient does not produce sufficient IgA overall. In IgA-deficient patients, IgG-based antibody tests — such as anti-gliadin IgG or deamidated gliadin peptide IgG — are used instead.

Additional serological markers used in celiac diagnosis include:

• Anti-endomysial antibody (EMA) IgA: Highly specific for celiac disease, but operator-dependent and less practical for routine screening
• Deamidated gliadin peptide (DGP) IgA and IgG: Useful, particularly in children under 2 years of age and in IgA-deficient patients
• Anti-reticulin antibody (ARA): Less commonly used in modern practice

Positive serology is followed by upper endoscopy with duodenal biopsy to confirm villous atrophy and establish the Marsh classification. Though in specific clinical contexts, some guidelines now accept diagnosis based on serology alone (particularly in children with TTG-IgA levels more than 10 times the upper limit of normal) (Husby et al., 2020).

The Gluten Challenge: Why You Must Be Eating Gluten Before Testing

Here is a critical piece of information patients often don’t receive: the TTG-IgA test only works if you are actively consuming gluten at the time of testing. The antibodies being measured are generated in response to ongoing immune exposure to gluten antigens. If you have already eliminated gluten from your diet — even for just a few weeks — your immune system begins to quiet down, antibody levels fall, and the test can return a false negative result even if you have true celiac disease.

The current recommendation from celiac disease guidelines is that patients should consume a “gluten challenge” — eating gluten at a level of at least 3 grams per day (roughly the amount in 1-2 slices of bread) for a minimum of 4 weeks before serological testing, and for at least 2 weeks before duodenal biopsy (Leffler et al., 2013).

For patients who are already gluten-free, this means deliberately reintroducing gluten before testing — which can be deeply unpleasant and is often met with resistance. But it is the only way to ensure the test’s diagnostic validity. A false negative result carries significant consequences: a patient with celiac disease who believes they have tested negative has no reason to maintain strict gluten elimination and may continue consuming gluten with devastating long-term health consequences.

I make it a clinical priority to ensure every patient I work with understands this requirement before undergoing celiac testing. The number of patients I have seen who have tested “negative” for celiac disease after months of gluten-free eating — and been reassured that they do not have celiac — only to continue struggling with the consequences of ongoing autoimmunity that was too quiet to detect at the time of testing, is genuinely concerning.

Dermatitis Herpetiformis: When Celiac Disease Manifests in the Skin

One of the most dramatic and frequently misdiagnosed manifestations of celiac disease is dermatitis herpetiformis (DH) — sometimes called “Duhring’s disease” — a skin condition that represents the cutaneous expression of celiac autoimmunity and is, in fact, considered a form of celiac disease rather than a separate disorder (Salmi, 2019).

The Pathophysiology of Dermatitis Herpetiformis

The mechanism of DH connects directly to the systemic antibody pathology of celiac disease. As I explained earlier, IgA antibodies produced in response to gluten ingestion target TTG and circulate throughout the body. In the skin — specifically in the dermal papillae, the small cone-shaped projections of dermal connective tissue that interdigitate with the overlying epidermis — IgA-gluten complexes become trapped.

The reason for this trapping involves both the anatomy of the dermal papillae (which receive rich capillary loops that may act as mechanical traps for circulating immune complexes) and the expression of epidermal transglutaminase (TG3) — a skin-specific isoform of transglutaminase that serves as a target for cross-reactive anti-TTG IgA antibodies (Sárdy et al., 2002).

Once IgA-gluten complexes are deposited in the dermal papillae, they activate the complement system and trigger mast cell degranulation and the influx of neutrophils to the skin. The result is a dramatic, intensely itchy dermatitis characterized by:

• Grouped, symmetrically distributed papules and vesicles — typically on the elbows, knees, buttocks, scalp, and back
• Intense pruritus (itching) that often precedes the visible skin lesions
• Burning and stinging sensations in affected areas
• Blistering that, when scratched or ruptured, leaves hyperpigmented skin

The DH rash is often misdiagnosed as eczema, contact dermatitis, or other inflammatory skin conditions. Skin biopsy with direct immunofluorescence establishes the correct diagnosis by revealing characteristic granular IgA deposits in the dermal papillae—a finding that is pathognomonic for DH/celiac disease.

Why Systemic Symptoms Accompany the Skin Manifestation

When IgA-gluten immune complexes are deposited in the skin and trigger mast cell degranulation, the resulting inflammatory cascade is not confined to the skin. Mast cells are among the most promiscuous inflammatory cells in the body — when activated, they release a vast repertoire of mediators including histamine, prostaglandins, leukotrienes, serine proteases, and cytokines. These mediators enter the circulation and contribute to the systemic symptom burden of celiac disease: fatigue, brain fog, joint pain, headaches, and a general sense of feeling profoundly unwell.

The cytokine overload that results from ongoing celiac autoimmunity also places significant stress on the adrenal glands, which are recruited to produce cortisol in an attempt to modulate the inflammatory response. Over time, the relentless demand for cortisol production leads to adrenal fatigue — not a recognized diagnostic category in conventional medicine, but a real physiological phenomenon in which the HPA axis becomes dysregulated after prolonged immune-inflammatory stress. This contributes to the profound fatigue and stress intolerance that many celiac patients experience.

The liver is also under continuous stress in active celiac disease. Elevated liver enzymes—particularly ALT and AST—are found in about 40% of untreated celiac patients and reflect either direct hepatic involvement (through anti-TTG antibodies targeting hepatic TG or immune complex deposition in the liver) or the hepatic burden of processing the systemic cytokine load (Bardella et al., 2004). In most cases, liver enzyme elevations normalize completely with strict gluten elimination — a powerful confirmation that the celiac autoimmunity, not some separate liver disease, was the driver.

Threshold Dynamics: The “Bucket Model” of Gut Stress and Why Celiac Disease Appears in Adulthood

One of the most common and genuinely puzzling questions I hear from patients newly diagnosed with celiac disease is this: “I’ve been eating wheat my whole life. Why am I only getting sick now, in my forties?”

This question deserves a thorough, scientifically grounded answer — and the bucket model of threshold dynamics provides it elegantly.

The Concept of Threshold Dynamics in Gut Immune Physiology

The human gut is not static. It is a dynamic ecological and immunological environment that is shaped continuously by the foods we eat, the medications we take, the infections we encounter, the stress we experience, and the microbiome we cultivate or erode over a lifetime. The resilience of the gut — its capacity to tolerate antigenic challenges, maintain barrier integrity, and regulate immune responses without catastrophic overreaction — is not infinite. It is capacity-limited.

I use the bucket model to explain this to patients: imagine the gut’s total stress capacity as a bucket. Over the course of a lifetime, various stressors slowly fill that bucket:

• Repeated antibiotic courses that disrupt the microbiome
• Chronic psychological stress that activates the HPA axis and impairs gut motility and barrier function through cortisol and CRH signaling
• Dietary patterns high in processed foods, sugar, refined oils, and food additives like emulsifiers and artificial sweeteners that damage the mucosal barrier
• Proton pump inhibitor (PPI) use that alters gastric pH and microbiome composition.
• NSAID use that directly damages the intestinal epithelium through inhibition of prostaglandin synthesis
• Recurrent viral infections, particularly gastrointestinal viruses, that disrupt tight junction integrity
• Sleep deprivation, which impairs mucosal immunity and promotes intestinal permeability
• Environmental toxins including glyphosate — the herbicide used extensively on wheat crops — which has been shown in animal models to increase intestinal permeability and alter microbiome composition (Samsel & Seneff, 2013)

Each of these stressors contributes incrementally to the total load in the bucket, slowly eroding the microbiome’s diversity and resilience, gradually weakening the tight junction network, and progressively compromising the intestinal immune regulatory machinery.

For decades, this gradual accumulation may occur without any clinically apparent consequences. The genetic susceptibility is there — the HLA-DQ2 or HLA-DQ8 genes are present — but the gut’s homeostatic mechanisms are just barely keeping the bucket from overflowing. The person eats wheat their whole life, perhaps feels a little bloated occasionally, perhaps gets tired after a heavy pasta meal, but nothing that rises to the level of a recognizable clinical syndrome.

And then, at some point — perhaps after a particularly stressful period, a significant illness, a major surgery, a bereavement, a pregnancy, or a period of intensive antibiotic use — the bucket overflows. The microbiome is sufficiently disrupted, the tight junction network is sufficiently weakened, and the intestinal epithelium is sufficiently inflamed that gliadin peptides can now breach the barrier in meaningful quantities.

From Tolerance to Immune Attack: The Transition Point

What changes when the bucket overflows is not just the amount of gliadin reaching the immune cells of the lamina propria — it is the immunological context in which that gliadin is encountered. A healthy, intact gut with a robust microbiome creates a tolerogenic immune environment — an environment in which foreign food antigens are processed and met with immune tolerance rather than immune attack. Regulatory T cells (Tregs) and specific microbial metabolites—particularly short-chain fatty acids (SCFAs) like butyrate— maintain this tolerogenic environment by promoting Treg differentiation and suppressing inflammatory T cell responses (Furusawa et al., 2013).

When the microbiome is significantly disrupted — whether by antibiotics, poor diet, chronic stress, or other factors — butyrate production falls, Treg populations decline, and the gut immune environment shifts from tolerogenic to inflammatory. In this primed, inflamed state, when gliadin peptides breach the damaged tight junctions and encounter antigen-presenting cells, the immune response is no longer tolerant. In a genetically susceptible individual, it becomes adaptive, specific, and destructive — the beginning of celiac autoimmunity.

This explains why celiac disease can remain silent for decades and then appear to “switch on” seemingly overnight. The switch, in fact, has been slowly accumulating for years or decades, waiting for the bucket to overflow.

Clinical Implications of the Threshold Model

The bucket model has profound implications for both prevention and treatment:

For patients with a genetic risk of celiac disease (those with HLA-DQ2/DQ8 positivity or a family history of celiac disease), the model suggests that minimizing the cumulative gut stress load — protecting microbiome diversity, avoiding unnecessary antibiotics, managing stress, eating a nutrient-dense diet, and minimizing NSAID use — may significantly delay or even prevent the expression of clinical celiac disease.

For patients who have already developed celiac disease, the model reminds us that gluten elimination — while necessary — is not the only intervention required. The bucket must also be emptied. This means addressing the microbiome, healing the mucosal barrier, correcting nutrient deficiencies, reducing chronic stressors, and supporting the immune regulatory mechanisms that, in a healthy gut, should maintain tolerance. This is the domain of functional medicine — and it is central to the care we provide at Injury Medical Clinic PA.

For patients with NCGS, the bucket model is even more actionable. Because NCGS is a reversible innate immune response rather than a permanent adaptive autoimmune process, comprehensive gut-healing protocols can empty the bucket and restore the gut’s tolerogenic capacity, so you may eventually reintroduce gluten without triggering symptoms.

The Molecular Cascade of Mast Cell Degranulation and Cytokine Overload in Celiac and NCGS

Both celiac disease and NCGS — through their respective immune mechanisms — ultimately converge on mast cell activation and the release of inflammatory mediators that produce many of the most distressing symptoms patients experience. Understanding this shared downstream pathway helps explain why the symptom profiles of the two conditions can overlap, even as their underlying mechanisms differ.

Mast Cells: Sentinels of the Mucosal Immune System

Mast cells are resident immune cells found throughout the body’s mucosal surfaces — including the intestinal mucosa — as well as in the skin, lungs, and connective tissues. They are densely packed with cytoplasmic granules containing pre-formed inflammatory mediators, ready for immediate release upon activation. In the gut, mast cells function as key orchestrators of the mucosal immune response, positioned to sense danger signals from both the lumen and the underlying tissue and to coordinate the appropriate defensive response.

Mast cells can be activated through multiple mechanisms relevant to gluten-related disorders:

• IgE-mediated activation: Through cross-linking of IgE antibodies bound to the high-affinity Fc?RI receptor on the mast cell surface (the classic allergy mechanism — not the primary mechanism in celiac or NCGS)
• IgA-mediated activation: Through IgA immune complexes binding to Fc?RI receptors — directly relevant to celiac disease, where IgA-gluten-TTG complexes activate mast cells in the intestinal mucosa and skin
• Innate immune receptor activation: Through TLR signaling, NLRP3 inflammasome activation, and complement-mediated mechanisms — relevant to NCGS, where ATI-driven TLR4 activation can directly trigger mast cell degranulation (Vanuytsel et al., 2014)
• Neuropeptide-mediated activation: Through substance P, corticotropin-releasing hormone (CRH), and other stress neuropeptides — creating the crucial link between psychological stress and gut inflammation that I will address further in the context of the bucket model

The Mediators of Mast Cell Degranulation and Their Clinical Effects

When intestinal mast cells degranulate in response to gluten-related immune activation, they release a comprehensive library of inflammatory mediators:

Histamine: Increases intestinal permeability (further aggravating the leaky gut), visceral hypersensitivity (pain), mucus secretion, and gut motility. Systemically, histamine causes vasodilation, pruritus, and the neurological symptoms associated with histamine intolerance — a condition that frequently coexists with celiac disease and NCGS.

Prostaglandins (particularly PGE2): Drive intestinal secretion, promote gut motility (contributing to diarrhea), increase vascular permeability, and amplify pain sensitivity through sensitization of nociceptors.

Leukotrienes: Potent pro-inflammatory lipid mediators that increase vascular permeability, recruit eosinophils and neutrophils, and amplify the inflammatory response.

Tryptase: A serine protease released by mast cells that activates PAR-2 receptors on intestinal epithelial cells and enteric neurons, further increasing intestinal permeability and visceral pain.

TNF-?: A master pro-inflammatory cytokine that coordinates the broader immune response, promotes intestinal permeability, drives cachexia and fatigue, and — in chronic excess — contributes to the systemic metabolic dysfunction seen in long-standing celiac disease.

IL-1?, IL-6: Pro-inflammatory cytokines that drive the acute phase response, fever, fatigue, and systemic inflammation. IL-6 is particularly significant because it promotes the differentiation of inflammatory Th17 cells while suppressing regulatory Treg populations—further shifting the immune balance toward inflammation.

The Experience of Cytokine Overload: Why Celiac Patients Feel So Ill

The collective effect of this cytokine storm — originating in the gut but rapidly becoming systemic — explains the profound and multidimensional sense of illness that celiac patients and NCGS patients report. The “sickness behavior” syndrome — characterized by fatigue, cognitive impairment (brain fog), reduced motivation, social withdrawal, increased pain sensitivity, disturbed sleep, and mood disturbances — is now understood to be a neurologically mediated response to peripheral cytokine signaling, driven primarily by IL-1, IL-6, and TNF-?, acting on the brain through multiple pathways (Dantzer et al., 2008).

When patients describe feeling “like they’ve been hit by a bus” after a gluten exposure, or experiencing days of debilitating brain fog and exhaustion following a restaurant meal containing hidden gluten, they are describing the physiological reality of cytokine-mediated sickness behavior — a genuine biological response, not a psychological reaction.

This understanding should reframe how we approach these patients clinically. These are not people who are “sensitive” in the pejorative sense or who need to be toughened up. Their immune systems generate powerful cytokine signals in response to a dietary trigger, and those signals produce predictable, measurable neurobiological effects on brain function and behavior.

Cross-Reactivity and Molecular Mimicry: Why Dairy Is a Problem in Celiac Disease

One of the recommendations I make that often surprises celiac patients is the need to also eliminate dairy — at least during the initial healing phase and in many cases permanently. This involves two immunological phenomena: cross-reactivity and molecular mimicry.

Cross-Reactivity: Shared Antigens Between Gluten and Dairy

Cross-reactivity occurs when antibodies or T cells raised against one antigen react with a structurally similar but distinct antigen. In celiac disease, the immune system generates antibodies and sensitized T cells against specific gluten-derived peptide sequences—particularly certain sequences within alpha-gliadin.

Research by Aristo Vojdani and colleagues has shown that antibodies raised against wheat/gliadin cross-react significantly with multiple food antigens, including casein and butyrophilin—proteins found in dairy products (Vojdani & Tarash, 2013). This cross-reactivity stems from structural similarity between certain amino acid sequence motifs in gliadin and casein.

The clinical consequence is that consuming dairy may, in some celiac patients, trigger the same antibody-mediated immune response as consuming gluten — not because the dairy contains gluten, but because the immune system cannot reliably distinguish between the two structurally similar protein motifs. This explains why some celiac patients who are strictly gluten-free continue to experience symptoms and continued intestinal inflammation if they are consuming dairy.

Molecular Mimicry: When the Immune Response Loses Its Boundaries

Molecular mimicry is a related but distinct phenomenon. It refers to the situation where an immune response raised against a foreign protein (such as gliadin) produces antibodies or T cells that cross-react with the body’s own proteins — not because of shared structure between the food protein and the pathogen, but because of shared structure between the food protein and host tissue proteins.

In celiac disease, the most important example of molecular mimicry involves the resemblance between certain gliadin peptide sequences and sequences found in host proteins expressed in the brain, joints, thyroid gland, and other tissues. This provides a mechanistic explanation for the diverse extra-intestinal manifestations of celiac disease — the neurological damage, the joint involvement, the thyroid dysfunction — that go well beyond what one would expect from a simple gut disease.

The thyroid connection is clinically important. Hashimoto’s thyroiditis — the most common autoimmune thyroid disease — occurs at a significantly higher rate in celiac patients than in the general population. Molecular mimicry is implicated: antibodies generated against gliadin cross-react with thyroid peroxidase (TPO) and thyroglobulin, potentially initiating or amplifying the autoimmune attack on the thyroid gland (Sategna-Guidetti et al., 2001). This is one reason I always evaluate thyroid function in newly diagnosed celiac patients and why strict gluten elimination often improves thyroid antibody levels.

Integrative Chiropractic Care in the Management of Celiac Disease and NCGS

Now I want to address something I recognize may initially seem surprising to some readers: the role of chiropractic care in managing gluten-related immune disorders. This is not about treating the gut with spinal manipulation, and I want to be clear about that. Rather, it is about understanding the profound and bidirectional relationship between spinal health, the nervous system, and gut immune function — and recognizing that the patient with celiac disease or NCGS is a whole person whose suffering extends well beyond the intestinal mucosa.

The Gut-Brain-Spine Axis: A Bidirectional Communication Network

The gut, the brain, and the spine are connected through an extraordinarily complex bidirectional communication network that encompasses the vagus nerve, the enteric nervous system (ENS), the autonomic nervous system, and the HPA axis. This network—the gut-brain axis—coordinates digestive function, immune regulation, mood, cognition, and stress responses in ways modern neuroscience is only beginning to appreciate (Cryan et al., 2019).

The vagus nerve— the tenth cranial nerve and the longest autonomic nerve in the body—carries 80% of its information from the gut to the brain (afferently), relaying information about intestinal contents, motility, inflammation, and microbiome composition to the central nervous system. The brain, in turn, sends efferent signals through the vagus nerve to regulate intestinal immune function, motility, and secretion.

Vagal tone — the background activity level of the vagus nerve — is a critical determinant of gut immune regulation. High vagal tone is associated with anti-inflammatory gut function, including suppression of TNF-? production by intestinal macrophages through the cholinergic anti-inflammatory pathway (Tracey, 2002). Low vagal tone—associated with chronic stress, poor posture, and spinal dysfunction—is linked to pro-inflammatory gut function and has been associated with increased intestinal permeability and dysregulated gut immune responses.

How Spinal Dysfunction Affects Gut Immune Function

The thoracic spine (T5-T9) houses the sympathetic nerve roots that innervate the small intestine. Subluxations or areas of somatic dysfunction in the thoracic spine can alter sympathetic tone to the gut, affecting motility, secretion, mucosal blood flow, and immune cell trafficking in the intestinal wall (Leach, 2008). Increased sympathetic tone to the gut is known to:

• Reduce mucosal blood flow and oxygen delivery to intestinal epithelial cells.
• Decrease production of secretory IgA (sIgA) — the principal antibody of mucosal immunity
• Impair intestinal motility, contributing to constipation and altered microbiome composition.n
• Increase intestinal permeability through neurogenic mechanisms
• Promote mast cell degranulation in the gut wall through substance P release from sympathetic nerve endings

Chiropractic adjustments targeting the thoracic spine — particularly the T5-T9 levels — can reduce sympathetic hyperactivity and improve autonomic balance, potentially supporting gut mucosal function and immune regulation. While direct clinical trials specifically examining chiropractic adjustments in celiac disease patients are limited, the neurophysiological rationale is well established, and clinical observations from my practice support this approach as part of comprehensive integrative care.

Addressing the Musculoskeletal Consequences of Celiac Disease

Beyond the neurophysiological rationale, chiropractic care directly addresses the musculoskeletal manifestations of celiac disease that create significant suffering for patients:

Osteoporotic compression fractures: The severe vitamin D and calcium malabsorption of untreated celiac disease produces dramatic bone density loss. Patients may present with compression fractures of the thoracic and lumbar spine — a presentation that in younger patients should always prompt evaluation for underlying malabsorption syndromes. Chiropractic care must be carefully adapted for patients with established osteoporosis (avoiding high-velocity manipulation of compromised vertebrae). Still, gentle mobilization, soft tissue therapy, and therapeutic exercise programs can improve function, reduce pain, and support the bone-loading mechanical stimulus essential for bone density maintenance.

Joint pain and arthropathy: Peripheral and axial arthropathy are recognized extra-intestinal manifestations of celiac disease, occurring in approximately 20% of patients (Lubrano et al., 1996). The mechanism involves immune complex deposition in synovial tissue and cytokine-mediated joint inflammation. Chiropractic care—including joint mobilization, soft tissue therapy, and rehabilitative exercise—directly addresses the functional limitations of this arthropathy and helps maintain joint mobility and muscle function. At the same time, dietary intervention helps control the underlying autoimmune process.

Muscle weakness and myopathy: Magnesium deficiency (from malabsorption), vitamin D deficiency (contributing to proximal myopathy), and general protein malabsorption all contribute to the muscle weakness and fatigue that celiac patients frequently experience. Rehabilitative exercise protocols—integrated with nutritional supplementation to address deficiencies— are essential for recovery. Our rehabilitation team at Injury Medical Clinic PA designs individualized exercise programs that account for the patient’s current strength, nutritional status, and bone density to rebuild musculoskeletal function safely.

Chronic pain syndromes: The neurological complications of celiac disease — peripheral neuropathy, gluten ataxia, and central sensitization driven by chronic cytokine exposure — contribute to complex chronic pain syndromes that are frequently mismanaged in conventional care. My team and I approach these presentations using a biopsychosocial model, incorporating chiropractic neurology techniques, manual therapy, low-level laser therapy (LLLT), rehabilitative movement, and mind-body interventions to address the multiple dimensions of the pain experience.

Functional Medicine Assessment: The Foundation of Integrative Care

Every clinical encounter in our practice begins with a functional medicine assessment—a systematic, evidence-based approach to identifying the root causes of health dysfunction rather than simply managing symptoms. In the context of gluten-related immune disorders, our functional medicine assessment includes:

Advanced laboratory evaluation:

• Complete celiac serology panel (TTG-IgA, EMA, DGP IgA/IgG, total IgA)
• Comprehensive food reactivity testing (IgG and IgA panels for multiple food antigens)
• Comprehensive stool analysis with microbiome profiling
• Intestinal permeability markers (zonulin, lactulose/mannitol ratio)
• Full nutrient status panel (iron, ferritin, vitamin D, B12, folate, zinc, magnesium, calcium, fat-soluble vitamins)
• Inflammatory markers (CRP, ESR, IL-6, TNF-?)
• Complete thyroid panel (TSH, free T3, free T4, anti-TPO, anti-thyroglobulin)
• HbA1c and fasting glucose (insulin resistance is common in the context of gut dysbiosis)
• Comprehensive metabolic panel including liver function tests
• Genetic testing including HLA-DQ2/DQ8 haplotyping when appropriate

Microbiome evaluation: Disruption of the gut microbiome—dysbiosis—contributes to and results from celiac disease and NCGS. Comprehensive stool analysis identifies patterns of bacterial imbalance, presence of potentially pathogenic organisms, levels of beneficial fermenters (Bifidobacterium, Lactobacillus, butyrate producers), and markers of intestinal inflammation and permeability.

Nutritional assessment and diet optimization: Beyond gluten elimination, functional medicine nutritional assessment evaluates the overall dietary pattern for foods that may be contributing to intestinal inflammation (other food sensitivities, high-FODMAP foods, artificial additives), nutrient gaps that require therapeutic supplementation, and opportunities to support gut healing through targeted nutritional intervention.

The Gut Healing Protocol: A Functional Medicine Approach

For patients with celiac disease, the foundation of the gut healing protocol is absolute, lifelong gluten elimination. Full stop. No exceptions. No “just a little bit.” The adaptive immune response that defines celiac disease does not have a dose-response threshold in the conventional sense—no gluten exposure in a sensitized individual can re-trigger the immune cascade, and even small amounts of contamination can cause ongoing villous damage in the most sensitive patients (Biagi et al., 2010).

For patients with NCGS, and as a complementary intervention for celiac patients during the mucosal healing phase, our functional medicine gut healing protocol — informed by the “5R Framework” commonly used in functional medicine — proceeds through the following phases:

1. Remove: Eliminate gluten and all cross-reactive foods (particularly dairy in celiac patients). Remove other identified food sensitivities. Reduce or eliminate additional gut stressors: NSAIDs, artificial sweeteners, emulsifiers, excess alcohol, refined sugar, and high-pesticide foods.
2. Replace: Support digestive function with targeted enzyme supplementation — including dipeptidyl peptidase IV (DPP-IV), an enzyme specifically involved in gliadin digestion, which may reduce the burden of undigested gliadin peptides during the transition period. Additionally, support betaine HCl if hypochlorhydria is present, and ox bile or lipase enzymes if fat malabsorption is documented.
3. Reinoculate: Restore microbiome diversity through probiotic supplementation targeting clinically relevant species — particularly Lactobacillus rhamnosus GG, Bifidobacterium longum, Bifidobacterium infantis, and specific strains with demonstrated efficacy in reducing intestinal permeability. Support prebiotic fiber intake (where tolerated) to nourish beneficial microbiota.
4. Repair: Support mucosal healing through targeted nutrients:

• L-glutamine: The primary fuel source for intestinal enterocytes, essential for maintaining tight junction integrity and supporting epithelial repair (Coeffier et al., 2010)
• Zinc carnosine: Specifically supports gastric and intestinal mucosal healing and tight junction expression
• Colostrum: Rich in growth factors (EGF, IGF-1) and sIgA that support mucosal regeneration
• Vitamin D: Beyond its role in bone health, vitamin D plays a critical role in gut immunity, tight junction regulation, and mucosal defense
• Omega-3 fatty acids (EPA/DHA): Anti-inflammatory, support mucosal healing, modulate cytokine production
• Curcumin: Potent NF-?B inhibitor that reduces intestinal inflammation and supports mucosal barrier function
• Quercetin: Supports tight junction expression, inhibits mast cell degranulation, and has anti-inflammatory properties.
• S. cerevisiae boulardii: A beneficial yeast with demonstrated ability to reduce intestinal permeability and support mucosal IgA secretion

5. Rebalance: Address lifestyle factors that continue to stress the gut: chronic psychological stress (through mindfulness-based interventions, breathing exercises, and targeted stress management), sleep optimization, exercise, and ongoing dietary refinement.

The Role of Internal Medicine in Managing Celiac Disease and NCGS: Dr. Cardenas’s Contribution

While my chiropractic and functional medicine expertise drives the integrative framework of our clinical approach, Dr. Maria Guadalupe Cardenas, MD, as Medical Director, is indispensable—particularly in managing the systemic medical complications of celiac disease and ensuring patients receive appropriate conventional medical evaluation alongside our integrative interventions.

Medical Oversight for Complex Systemic Presentations

Internal medicine is the specialty best positioned to manage the multi-system complexity of celiac disease. An internist with Dr. Cardenas’s depth of experience — over 40 years of clinical practice — brings not only the breadth of medical knowledge required to recognize and manage celiac’s diverse systemic manifestations, but also the clinical wisdom to prioritize appropriately, to know when to investigate further, and to know when conventional medical intervention is necessary alongside integrative approaches.

In our collaborative model at Injury Medical Clinic PA, Dr. Cardenas provides:

• Medical evaluation and diagnosis: Including ordering and interpreting the full celiac serology panel, referring for endoscopy with biopsy when indicated, and coordinating with gastroenterology when necessary
• Management of systemic complications: Including medical management of metabolic bone disease, anemia, thyroid disorders, cardiovascular risk factors, and liver enzyme elevations
• Pharmacological oversight: Including appropriate prescription of nutritional supplements at therapeutic doses (prescription-grade vitamin D, iron supplementation, B12 injections when oral absorption is insufficient), and management of any concurrent medical conditions
• Monitoring for celiac-associated malignancies: Untreated celiac disease is associated with an increased risk of intestinal T-cell lymphoma, small bowel adenocarcinoma, and other malignancies. Regular follow-up and appropriate surveillance is an important component of long-term celiac management (Biagi & Corazza, 2002)
• Management of refractory celiac disease: A subset of celiac patients — approximately 5% — do not respond to strict gluten elimination and may have refractory celiac disease (RCD), which requires specialist medical management including immunosuppressive therapy. Dr. Cardenas’s expertise ensures that patients with unexpectedly poor responses to dietary intervention receive appropriate escalation of care.

The Collaborative Model works so effectively—and I believe it represents the future of complex chronic disease management—because the combined clinical perspectives of Dr. Cardenas and me create something neither of us could achieve alone.

Conventional internal medicine is extraordinarily effective at identifying, diagnosing, and managing the acute and severe manifestations of celiac disease. But it has historically been less equipped to address upstream contributors to gut immune dysfunction, microbiome disruption, nutrient deficiencies, lifestyle factors, spinal and musculoskeletal consequences, and the comprehensive dietary and lifestyle optimization that drives long-term healing.

Functional medicine and chiropractic care, conversely, are highly effective at addressing these upstream factors, but require the grounding of rigorous medical evaluation, diagnostic precision, and pharmacological oversight that internal medicine provides.

Together, these approaches create a clinical environment where patients receive the best of both worlds: the diagnostic rigor and medical safety of conventional internal medicine, integrated with the comprehensive, root-cause-oriented, lifestyle-focused care of functional and chiropractic medicine.

Personal Injury and Celiac Disease: An Often-Overlooked Connection

An important and clinically relevant intersection that I address regularly in my practice — as a clinic that specializes in personal injury care — is the potential relationship between physical trauma and the activation or exacerbation of celiac disease and NCGS.

Physical Trauma as a Gut Stressor

Physical trauma — whether from motor vehicle accidents, falls, sports injuries, or surgical procedures — represents a significant physiological stressor with direct effects on gut function and immune regulation. The mechanisms include:

Neurogenic intestinal inflammation: Physical trauma activates the sympathetic nervous system and the HPA axis, triggering the release of corticotropin-releasing hormone (CRH) from both central and peripheral (enteric) sources. CRH potently activates intestinal mast cells and directly increases intestinal permeability (Vanuytsel et al., 2014).

Post-traumatic gut dysbiosis: The physiological stress response following trauma — including altered motility, reduced mucosal blood flow, and immune suppression — creates conditions favorable for dysbiosis, particularly overgrowth of potentially pathogenic bacteria. Dysbiosis, as I discussed in the bucket model, is a key contributor to the conditions that allow celiac disease to emerge or worsen.

Trauma-related medication use: Personal injury patients are frequently prescribed NSAIDs for pain management. As mentioned earlier, NSAIDs directly damage the intestinal epithelium and increase intestinal permeability, potentially serving as the “tipping point” that pushes a genetically susceptible individual over the threshold into clinical celiac disease or NCGS.

Spinal trauma and autonomic dysregulation: Injuries to the cervical and thoracic spine — common in whiplash injuries and other personal injury presentations — can produce lasting changes in autonomic nervous system function, including altered vagal tone and changes in sympathetic innervation to the gut. As I described earlier, these autonomic changes can directly impact gut immune regulation and mucosal barrier function.

At Injury Medical Clinic PA, we therefore evaluate all personal injury patients for pre-existing or trauma-triggered gut immune dysfunction as part of our comprehensive assessment. The intersection of trauma and gut health is a clinical reality that deserves more attention in both the personal injury and gastroenterology communities, and our integrative model positions us well to address it.

Advanced Diagnostic Considerations: Beyond the Standard TTG IgA Test

While the TTG-IgA test remains the cornerstone of celiac disease serology, the diagnostic landscape for gluten-related disorders is considerably more nuanced than a single test can capture. I want to outline the additional diagnostic tools our integrative approach uses to provide the most comprehensive picture of each patient’s gut immune status.

Comprehensive Food Reactivity Testing

IgG-mediated food sensitivities — distinct from both celiac disease (IgA/IgG autoimmunity) and classic IgE-mediated food allergy — represent a third category of adverse food reaction that is highly relevant in the clinical context of gut immune dysfunction. IgG food sensitivity testing measures delayed immune reactions to specific food proteins, with a positive result indicating that the immune system has generated IgG antibodies against that food.

The conventional literature debates the clinical interpretation of IgG food testing. Still, in functional medicine practice, these results guide elimination and reintroduction protocols rather than serving as definitive diagnoses. The underlying principle is that a leaky gut allows undigested food proteins to cross into the bloodstream, where IgG antibodies tag them— essentially creating a map of the foods generating the most immune burden in the context of impaired intestinal permeability.

When the gut heals and barrier integrity is restored, IgG reactivity to previously problematic foods typically diminishes—consistent with the view that these reactions result from gut permeability rather than intrinsic food intolerances.

Organic Acids Testing

Organic acids testing (OAT) — typically performed on a first-morning urine sample — provides a window into a wide range of metabolic processes, including mitochondrial function, B vitamin status, oxidative stress, detoxification capacity, and markers of gut dysbiosis (specifically, the presence of bacterial and yeast/fungal metabolites that indicate microbial overgrowth).

In the context of celiac disease and NCGS, OAT can reveal dysbiosis patterns, B vitamin deficiencies (particularly thiamine, riboflavin, B6, and folate), mitochondrial dysfunction secondary to nutrient malabsorption, and elevated oxidative stress markers — all of which guide targeted nutritional intervention.

Microbiome Analysis

Comprehensive stool microbiome analysis using 16S rRNA sequencing or shotgun metagenomics provides detailed information about the composition and diversity of the gut microbiome—information essential for designing effective probiotic and prebiotic interventions and monitoring treatment response.

In celiac disease, specific patterns of microbiome disruption have been documented, including reduced abundance of butyrate-producing bacteria (particularly Faecalibacterium prausnitzii and Roseburia species), reduced Bifidobacterium and Lactobacillus populations, and increased relative abundance of potentially pro-inflammatory bacteria such as Bacteroides vulgatus and certain Proteobacteria (Caminero et al., 2016). These patterns are relevant not only because they contribute to gut immune dysregulation but also because some gut bacteria — particularly certain Lactobacillus and Bacillus species — possess prolamyl endopeptidase activity that can digest gluten peptides, suggesting a role for specific probiotic strains in reducing the immunostimulatory burden of dietary gluten (Francavilla et al., 2012).

Intestinal Permeability Testing

Direct measurement of intestinal permeability can be accomplished through several methods:

• Lactulose/mannitol ratio (LMR) test: Measures the ratio of two non-metabolized sugars — large lactulose (which should not cross an intact epithelium) and small mannitol (which should) — in urine after oral ingestion. An elevated ratio indicates increased paracellular permeability.
• Serum zonulin measurement: Elevated serum zonulin indicates increased signaling for tight junction opening. Some caution is warranted when interpreting serum zonulin, as the commonly used ELISA assay may detect other proteins in the complement/properdin family. Still, it remains a useful clinical marker when interpreted in context.
• Serum LPS and LPS-binding protein: Elevated levels indicate endotoxemia — the translocation of bacterial LPS across a permeable intestinal barrier — and serve as a marker of significant gut permeability with systemic immune consequences.

The Neurological Dimension of Celiac Disease: Gluten Ataxia, Peripheral Neuropathy, and Cognitive Function

I want to return to the neurological consequences of celiac disease and explore them in greater depth, because they are among the most serious, most frequently missed, and most impactful consequences of untreated gluten autoimmunity — and because they are areas where the integrative approach I practice, combining chiropractic neurology with functional medicine, offers particularly meaningful clinical benefit.

Gluten Ataxia: Cerebellar Destruction by Antibody

Gluten ataxia is defined as sporadic ataxia in the presence of anti-gliadin antibodies in the absence of any other identifiable cause (Hadjivassiliou et al., 2003). It accounts for approximately 40% of all idiopathic ataxias and 15% of all ataxias in general — making celiac-related cerebellar pathology far more common than its obscurity in mainstream medical education would suggest.

The cerebellum, as the brain structure responsible for coordinating voluntary movement, maintaining balance, and regulating fine motor control, when damaged, produces the characteristic clinical picture of ataxia: wide-based, lurching gait, loss of hand coordination, dysarthria (slurred speech), nystagmus (involuntary eye movements), and impaired balance.

The immunological mechanism involves anti-TTG antibodies — specifically anti-TG6 antibodies — cross-reacting with Purkinje cells of the cerebellar cortex. Purkinje cells, the large, elaborately branched neurons that are the sole output of the cerebellar cortex, express TG6 on their surfaces, making them targets for the same antibody-mediated attack that destroys intestinal villi. Post-mortem examination of cerebella from gluten ataxia patients reveals Purkinje cell loss, inflammatory infiltrates, and posterior column degeneration — pathological findings remarkably similar to those seen in other autoimmune cerebellar conditions (Hadjivassiliou et al., 2010).

The critical clinical message is that the window for effective intervention in gluten ataxia is time-limited. Early detection and strict gluten elimination can halt the progression of cerebellar damage and, in patients with relatively short disease duration, produce meaningful recovery of cerebellar function. In patients with long-standing, undetected gluten ataxia, the loss of Purkinje cells is irreversible — underscoring the devastating consequences of diagnostic delay.

Peripheral Neuropathy: A Multi-Mechanism Problem

Peripheral neuropathy in celiac disease arises through multiple concurrent mechanisms, making it a complex and heterogeneous presentation:

Direct antibody-mediated neural damage: Anti-gliadin and anti-TTG antibodies have been demonstrated to bind to peripheral nerve tissue, potentially damaging axons and myelin sheaths through complement activation and cellular cytotoxicity.

Vitamin B12 deficiency neuropathy: The classic length-dependent sensorimotor neuropathy of B12 deficiency — with predominantly distal sensory loss, reduced ankle reflexes, and posterior column degeneration in the spinal cord — is well-recognized and directly attributable to the impaired ileal absorption of B12 in celiac disease.

Vitamin B6 deficiency neuropathy: Pyridoxine deficiency, also common in celiac disease due to malabsorption, contributes to sensory neuropathy.

Vitamin E deficiency neuropathy: Fat-soluble vitamin E deficiency in the context of fat malabsorption produces a distinctive neuropathy with spinocerebellar ataxia, areflexia, and proprioceptive loss.

Thiamine deficiency neuropathy: Severe thiamine deficiency—which can occur with significant malabsorption—produces the painful peripheral neuropathy of beriberi, along with cardiovascular and potentially central nervous system consequences.

From a chiropractic neurology perspective, I evaluate patients with gluten-associated neuropathy using a comprehensive neurological examination that includes assessment of:

• Deep tendon reflexes (upper and lower extremity)
• Sensory testing — including pinprick, light touch, vibration, and proprioception (the latter particularly important in B12 and vitamin E neuropathy)
• Cerebellar testing — including finger-nose, heel-shin, rapid alternating movements, and Romberg’s test
• Gait analysis — particularly heel-toe walking (tandem gait), which is sensitive to cerebellar dysfunction
• Muscle strength testing — to identify the proximal muscle weakness characteristic of vitamin D myopathy

Brain Fog and Cognitive Impairment: The Gut-Brain Connection

Cognitive impairment — typically described by patients as “brain fog,” characterized by difficulty concentrating, impaired memory, slowed processing speed, and mental fatigue — is among the most commonly reported and most debilitating symptoms of both celiac disease and NCGS.

The mechanisms are multiple and interconnected:

Cytokine-induced neurotransmitter disruption: IL-1?, IL-6, and TNF-? — produced in excess during active celiac autoimmunity — activate the indoleamine 2,3-dioxygenase (IDO) enzyme in the brain, shunting tryptophan metabolism away from serotonin synthesis and toward the kynurenine pathway, producing neuroactive metabolites including quinolinic acid (an NMDA receptor agonist and excitotoxin) and kynurenic acid (an NMDA receptor antagonist) (Dantzer et al., 2011). The net effect is dysregulated glutamatergic and serotonergic neurotransmission, contributing to mood disturbances, cognitive impairment, and fatigue.

Gut microbiome-brain communication: The gut microbiome communicates with the brain through multiple pathways, including direct vagal nerve signaling, immune signaling, and the production of neuroactive metabolites — including short-chain fatty acids, neurotransmitter precursors (serotonin, GABA, dopamine precursors), and enteroendocrine hormones. In celiac disease, microbiome dysbiosis disrupts these communication pathways, contributing to the cognitive and mood symptoms that patients experience.

Cerebrovascular effects: Anti-TTG antibody-mediated damage to the cerebral endothelium may impair cerebral blood flow autoregulation and blood-brain barrier integrity, allowing systemic inflammatory signals to penetrate the central nervous system more effectively.

Nutritional contributors: Iron deficiency anemia impairs oxygen delivery to the brain; B12 deficiency impairs myelin synthesis and axonal conduction; folate deficiency impairs neuronal DNA repair and neurotransmitter synthesis — all contributing to the cognitive burden of untreated celiac disease.

Clinical Case Framework: How We Approach Gluten-Related Immune Disorders at Injury Medical Clinic PA

To illustrate how the scientific principles I have detailed throughout this post translate into clinical practice, let me walk through the general framework of how we approach a new patient presenting with suspected gluten-related immune disorder at Injury Medical Clinic PA.

Initial Clinical Evaluation

The initial evaluation begins with a comprehensive history — not just a focused gastrointestinal history, but a whole-person narrative that explores:

• Presenting symptoms and their timeline (onset, progression, triggering and relieving factors)
• Full dietary history including current and historical gluten consumption patterns
• Personal and family history of autoimmune conditions (celiac disease, Hashimoto’s thyroiditis, type 1 diabetes, rheumatoid arthritis, multiple sclerosis — all associated with celiac disease)
• Personal and family history of neurological conditions
• Medications (particularly antibiotics, NSAIDs, PPIs — all potential gut stressors contributing to the bucket)
• Detailed stress history and sleep quality
• Exercise habits and functional capacity
• History of trauma, accidents, or surgeries that may have contributed to gut or autonomic disruption

This is followed by a comprehensive physical examination incorporating:

• Gastroenterological assessment: Abdominal palpation for tenderness, organomegaly, or abnormal bowel sounds
• Musculoskeletal assessment: Joint mobility, muscle strength, evidence of arthropathy or osteopenia-related postural changes
• Neurological examination: As detailed above, with particular attention to signs of neuropathy, cerebellar dysfunction, and cognitive testing
• Dermatological assessment: Evaluation for the characteristic distribution of dermatitis herpetiformis
• Spinal assessment: Chiropractic assessment of spinal alignment, motion, and areas of somatic dysfunction with potential autonomic relevance
• Nutritional status indicators: Hair, skin, nail changes suggesting specific nutrient deficiencies; body composition; signs of muscle wasting

Laboratory and Diagnostic Ordering

Based on history and physical examination findings, we order the comprehensive laboratory panel outlined earlier — with particular attention to:

1. Confirming that the patient has been eating gluten regularly for at least 4 weeks before ordering celiac serology, or scheduling testing accordingly
2. Assessing the full spectrum of nutrient deficiencies likely to be present
3. Evaluating thyroid function and autoimmune thyroid status
4. Assessing cardiovascular risk markers in the context of the potential endothelial damage of celiac disease
5. Evaluating the microbiome and intestinal permeability status

Individualized Treatment Planning

Treatment planning is individualized based on the diagnosis and the full clinical picture:

For confirmed celiac disease: Strict, lifelong gluten and dairy elimination as the non-negotiable foundation, followed by comprehensive nutrient repletion, microbiome restoration, gut healing support, musculoskeletal rehabilitation where indicated, and ongoing medical monitoring by Dr. Cardenas.

For NCGS: Temporary gluten elimination (typically 6-12 weeks) as a diagnostic and therapeutic trial, combined with the full 5R gut healing protocol, microbiome evaluation and restoration, targeted nutritional support, identification and removal of other contributing food sensitivities (fructans/FODMAP evaluation), and progressive reintroduction of gluten under controlled conditions to assess tolerance restoration.

For both: Comprehensive stress management, sleep optimization, exercise programming, spinal assessment and chiropractic care where indicated, autonomic nervous system support, and ongoing monitoring of clinical response to dietary and lifestyle intervention.

The Science of Gut Healing: Why Time, Consistency, and Nutritional Support Are All Essential

One of the most important things I communicate to patients beginning the gut-healing journey is that healing takes time—and that time is only one required element.

The Timeline of Villous Recovery After Gluten Elimination in Celiac Disease

Contrary to what patients often hope, the intestinal mucosa in celiac disease does not heal overnight after gluten elimination. The timeline of histological recovery is highly variable and often prolonged:

• Serological markers (TTG-IgA levels) typically begin to fall within 3-6 months of strict gluten elimination, but may take 12-18 months to normalize in adults
• Symptomatic improvement often begins within weeks of gluten elimination, though this varies enormously
• Histological recovery (normalization of villous architecture on biopsy) is demonstrable in most patients within 1-2 years of strict dietary adherence — but a significant proportion of adults still show incomplete histological recovery even at 5 years after diagnosis, often due to inadvertent gluten exposure rather than true refractory disease (Rubio-Tapia et al., 2010)
• Bone mineral density may take several years of strict gluten elimination and aggressive nutritional support to normalize. It may never fully recover to age-matched normal values in patients diagnosed late in life.

This timeline has important clinical implications. A patient who is tested for celiac antibodies 6 weeks after diagnosis and treated as cured because their symptoms have improved has not been adequately followed up. Ongoing clinical monitoring by Dr. Cardena, including periodic repeat celiac serology, nutrient status assessment, bone density monitoring, and assessment for complications, is a standard component of our celiac management protocol.

The Role of Specific Nutrients in Gut Mucosal Healing

I want to provide additional detail on the specific nutritional interventions that support mucosal healing, because this is an area where the functional medicine evidence base is strong and clinically actionable:

L-Glutamine (5-15 grams/day): The predominant fuel for intestinal enterocytes, glutamine is essential for maintaining tight junction protein expression, supporting epithelial cell proliferation, and modulating intestinal immune function. Studies have demonstrated that glutamine supplementation reduces intestinal permeability in clinical conditions associated with increased gut permeability, including critical illness, inflammatory bowel disease, and post-surgical states (Coeffier et al., 2010; van der Hulst et al., 1993).

Vitamin D3 (doses tailored to achieve serum 25-OHD levels of 60-80 ng/mL): Beyond its roles in calcium absorption and bone health, vitamin D3 regulates tight junction expression (including occludin and claudin-1) and modulates intestinal immune responses toward tolerance (Kong et al., 2008). Vitamin D deficiency — nearly universal in active celiac disease — must be aggressively corrected with therapeutic supplementation doses under medical supervision, as standard daily reference intake doses are insufficient to normalize levels in malabsorbing patients.

Zinc (15-30 mg/day, balanced with copper): Zinc is a critical cofactor for intestinal alkaline phosphatase (IAP). This enzyme detoxifies bacterial LPS on the luminal surface of intestinal epithelial cells, reducing endotoxemia and intestinal inflammation. Zinc also supports epithelial cell proliferation and tight junction expression (Sturniolo et al., 2001).

Saccharomyces boulardii (5-10 billion CFU/day): This beneficial yeast has been clinically studied in multiple gastrointestinal conditions and demonstrates a consistent ability to reduce intestinal permeability, increase sIgA secretion, reduce bacterial translocation, and support mucosal healing (Czerucka et al., 2007).

Bovine colostrum: Rich in growth factors (EGF, IGF-1, TGF-?), immunoglobulins (IgA, IgG, IgM), lactoferrin, and proline-rich polypeptides, colostrum provides a broad range of mucosal-healing factors. A key caution in celiac disease: some bovine colostrum products may contain casein residues, so careful sourcing and product selection are essential. In practice, I use colostrum selectively and cautiously in celiac patients who have demonstrated tolerance to its use.

Curcumin (1-3 grams/day in bioavailable forms such as phytosome or liposomal): A potent inhibitor of the NF-?B signaling pathway — the master regulator of pro-inflammatory gene expression — curcumin has been shown to reduce intestinal epithelial permeability, inhibit mast cell activation, suppress inflammatory cytokine production, and support mucosal healing in animal and human studies (Wüst et al., 2009; Ukil et al., 2003).

Omega-3 fatty acids (EPA/DHA, 2-4 grams/day): Through conversion to resolvins and protectins — specialized pro-resolving mediators (SPMs) — omega-3 fatty acids actively promote the resolution of intestinal inflammation and support the transition from inflammatory to regenerative mucosal immune responses. The anti-inflammatory effects of omega-3 fatty acids include reduced production of pro-inflammatory eicosanoids (PGE2, LTB4), reduced expression of adhesion molecules on endothelial cells, and suppression of NF-?B activation in intestinal epithelial cells (Calder, 2013).

The Psychological and Emotional Dimensions of Gluten-Related Immune Disorders

No educational discussion of celiac disease and NCGS would be complete without acknowledging the profound psychological and emotional burden these conditions impose on patients — a burden that is too often minimized or ignored in conventional clinical encounters and that, in our integrative practice, receives the attention it deserves.

The Social and Emotional Cost of Strict Dietary Restriction

For most people, food is not merely fuel. It is culture, celebration, connection, comfort, and identity. A diagnosis of celiac disease — with its requirement for permanent, absolute gluten elimination across a vast and pervasive dietary category — can feel like a profound loss. Patients mourn the foods they can no longer eat, struggle with the social challenges of eating in restaurants, at family gatherings, or in workplace settings, and often feel isolated by their dietary requirements.

Dietary anxiety — a state of persistent worry and vigilance about food contamination that, in its most extreme forms, can significantly impair quality of life — is common in celiac disease and is a recognized contributor to the reduced quality of life scores reported by celiac patients even after achieving good dietary adherence and clinical remission (van Hees et al., 2013).

Rates of depression and anxiety are significantly elevated in celiac patients compared to the general population — and the relationship is bidirectional: the neurobiological effects of active celiac autoimmunity (cytokine-induced neurotransmitter disruption, microbiome dysbiosis, gut-brain axis dysfunction) contribute to mood disorders, while the psychosocial burden of the diagnosis and dietary restriction independently drives anxiety and depression (Addolorato et al., 2001).

Our Integrative Approach to Psychological Support

At Injury Medical Clinic PA, we take the psychological dimension of gluten-related immune disorders seriously as a clinical concern that deserves targeted support:

• Patient education — the kind of comprehensive, science-based education I am providing in this post — is itself a powerful therapeutic intervention. Understanding the “why” behind dietary restrictions and symptom experiences significantly improves patient adherence, reduces anxiety, and empowers patients to take ownership of their health journey.
• Mind-body interventions — including diaphragmatic breathing, mindfulness-based stress reduction (MBSR), and heart rate variability (HRV) biofeedback — are incorporated into our clinical framework to support autonomic regulation, reduce gut-brain axis dysfunction, and manage the stress component of the bucket that contributes to ongoing gut immune dysregulation.
• Nutritional psychiatry guidance—focusing on dietary patterns (beyond simply gluten elimination) that support brain health, neurotransmitter synthesis, and mood regulation—is provided as part of our functional medicine approach.
• We facilitate referrals for psychological support when indicated, including to therapists or counselors experienced in working with chronic health conditions.

Monitoring Treatment Response and Long-Term Management of Celiac Disease

Serological Follow-Up

After initiating a strict gluten-free diet, measure TTG-IgA levels every 3-6 months in the first year and annually thereafter until stable normalization is achieved. Persistent elevation of TTG-IgA despite reported dietary adherence is a clinical signal that warrants investigation for:

• Inadvertent gluten ingestion — the most common cause, often due to hidden gluten in processed foods, medications, or restaurant cross-contamination
• Refractory celiac disease — if inadvertent exposure has been ruled out
• Cross-reactive food reactions (dairy, other proteins) perpetuating the immune response

Nutritional Monitoring

Nutrient status should be reassessed at 6-12 month intervals during the healing phase, with monitoring of:

• Ferritin and complete blood count (iron status and anemia)
• 25-OH vitamin D (targeting 60-80 ng/mL with supplementation)
• Vitamin B12 (targeting high-normal serum levels; in patients with suspected malabsorption, intramuscular B12 supplementation by Dr. Cardenas may be necessary)
• Folate
• Zinc and magnesium (RBC levels preferred over serum levels for both)
• Bone density (DEXA scan): Baseline at diagnosis and repeat at 1-2 year intervals

Endoscopic Follow-Up

Repeat upper endoscopy with duodenal biopsy is recommended in patients with persistent symptoms or elevated serology after 12-24 months of strict dietary adherence, to assess mucosal healing and rule out refractory celiac disease or other mucosal pathology.

Emerging Research: Therapeutic Frontiers in Celiac Disease

While the strict gluten-free diet remains the only established treatment for celiac disease, emerging research is actively investigating pharmacological and biological interventions that may eventually offer additional therapeutic options — particularly for patients with refractory celiac disease or those who struggle with the challenge of maintaining perfect dietary adherence.

Enzyme Supplements: DPP-IV and Latiglutenase

Several gluten-digesting enzyme supplements are under investigation as potential adjuncts to the gluten-free diet:

DPP-IV (dipeptidyl peptidase IV): This endopeptidase cleaves proline-rich peptides, including immunodominant gliadin peptides. While DPP-IV cannot fully digest all immunogenic gluten peptides and cannot replace dietary elimination, it may reduce the immunogenic burden of small, inadvertent gluten exposures. Available in over-the-counter digestive enzyme products, it can serve as a safety net for accidental cross-contamination exposures and is a reasonable adjunct in our integrative protocol.

Latiglutenase (ALV003/TAK-062): A combination of two recombinant gluten-specific proteases (an endoprotease and a prolyl endopeptidase) specifically designed to degrade immunodominant gluten peptides in the stomach before they reach the small intestine. Clinical trials have shown that latiglutenase reduces mucosal injury associated with gluten challenge in celiac patients, and it is being developed as a pharmacological adjunct for patients with celiac disease who experience inadvertent gluten exposures (Murray et al., 2017).

Zonulin Pathway Inhibitors: Larazotide Acetate

Larazotide acetate (AT-1001) is a tight junction regulator — a synthetic octapeptide that acts as an antagonist of the zonulin receptor, preventing gliadin-induced opening of tight junctions. Clinical trials have demonstrated that larazotide acetate reduces intestinal permeability, decreases celiac symptom scores, and reduces mucosal inflammatory markers in celiac patients on a gluten-free diet who experience persistent symptoms (Leffler et al., 2012).

While not yet FDA-approved for clinical use at the time of this writing, larazotide acetate is a promising, mechanistically targeted intervention that directly addresses a key pathophysiological step in celiac disease—the gliadin-induced disruption of tight junctions.

Immunotherapy: Nexvax2 and Other Desensitization Approaches

Nexvax2 was a peptide-based immunotherapy designed to induce immune tolerance to the dominant HLA-DQ2-restricted gluten peptides that drive celiac autoimmunity — conceptually similar to allergen immunotherapy used in allergic conditions. While early-phase trials showed promise, the Phase 2 clinical trial (reported in 2019) did not meet its primary endpoints, and development was discontinued (Tye-Din et al., 2019).

Achieving immune tolerance to gluten in celiac patients through immunotherapy remains a compelling research objective, and ongoing work in this area—including approaches targeting regulatory T cells, modifying antigen presentation, and exploiting microbiome-based immunomodulation—continues to advance.

Microbiome Transplantation and Modulation

Given the central role of gut dysbiosis in both the development and maintenance of celiac immune dysregulation, microbiome-targeted interventions—including fecal microbiota transplantation (FMT)—are being investigated as potential therapeutic tools. Early-stage research in animal models of gluten sensitivity and in human pilot studies of FMT in various autoimmune conditions suggests that restoring a healthy, diverse microbiome may significantly modulate intestinal immune function (Hviid et al., 2021). While FMT is not yet a standard-of-care intervention for celiac disease, the trajectory of research in this area is promising.

Evidence-Based Nutritional Guidance for Celiac Disease and NCGS: Building a Healing Diet

Eliminating gluten—and dairy in celiac patients—is the foundation of dietary management. But beyond elimination, the question becomes: what should you eat? This is where functional medicine nutrition provides a roadmap that conventional dietary guidance rarely offers.

The Anti-Inflammatory, Nutrient-Dense Dietary Pattern

The healing diet I recommend for patients with celiac disease and NCGS is built around the following principles:

1. Maximize nutrient density: Given the legacy of malabsorption that patients with celiac disease carry, every meal is an opportunity to restore nutrient stores. This means prioritizing:

• Animal proteins (grass-fed beef, wild-caught salmon, pasture-raised poultry and eggs, organ meats) for complete amino acids, iron, B12, zinc, and fat-soluble vitamins
• Colorful vegetables and fruits for phytonutrients, fiber, and antioxidants that support mucosal healing
• Root vegetables and starchy tubers (sweet potatoes, yams, squash) as gluten-free complex carbohydrate sources
• Nuts, seeds, and avocados for healthy fats, vitamin E, magnesium, and zinc
• Bone broth for glycine, proline, and collagen peptides that support gut lining integrity

2. Prioritize fermented foods (where tolerated): Sauerkraut, kimchi, kefir (if dairy is tolerated), kombucha, and yogurt (again, if dairy is tolerated) provide living microorganisms and organic acids that support microbiome diversity and gut immune regulation. In patients with significant dysbiosis or histamine intolerance, introduce fermented foods gradually after initial gut healing.
3. Minimize processed foods: Even “gluten-free” processed foods are frequently loaded with refined starches, seed oils, added sugars, and food additives that drive intestinal inflammation and dysbiosis. The goal is real food first — minimally processed whole foods that nourish rather than inflame.
4. Manage FODMAPs where indicated: For patients with significant overlapping NCGS-IBS symptoms driven by fructans or other FODMAPs, a structured low-FODMAP protocol under dietitian supervision can be highly effective — but should be time-limited rather than permanent, to avoid the microbiome-depleting effects of long-term low-fiber intake.
5. Address histamine burden where needed: Mast cell activation in celiac disease and NCGS can drive histamine intolerance—a condition in which the patient cannot adequately break down dietary histamine due to reduced DAO (diamine oxidase) enzyme activity. A low-histamine dietary approach combined with DAO enzyme supplementation can significantly reduce symptoms in affected patients.

A Message of Hope: Recovery Is Possible

I want to conclude this educational journey with the message I deliver to every patient I see with a gluten-related immune disorder: there is a path forward.

For patients with celiac disease, strict gluten elimination stops the immune attack. The gut heals. Nutrients are restored. Bone density recovers. Neurological damage, caught early enough, stabilizes or reverses. The systemic inflammation quiets. The fatigue lifts. The brain fog clears. The skin heals. This does not happen overnight, and it requires commitment, vigilance, and the right clinical support — but it happens. Every day, in practices like ours, patients reclaim their lives from celiac disease.

For patients with NCGS, the news is even more directly hopeful: the condition is reversible in most cases. With comprehensive gut healing, microbiome restoration, and appropriate nutritional support, we can restore the gut’s barrier and immune regulatory functions. Some patients ultimately regain the ability to tolerate gluten; others choose to remain gluten-free because they feel so much better. Both outcomes are valid. What matters is understanding the biology well enough to make empowered, informed choices.

Our team at Injury Medical Clinic PA — Dr. Cardenas providing the depth of internal medicine expertise, and I providing the breadth of chiropractic, functional medicine, and integrative clinical perspective — is committed to walking every patient through that journey with science, compassion, and clinical excellence.

References

Addolorato, G., Capristo, E., Ghittoni, G., Valeri, C., Mascianà, R., Ancona, C., & Gasbarrini, G. (2001). Anxiety but not depression decreases in coeliac patients after a one-year gluten-free diet and is related to autoimmunity levels rather than duration of disease. European Journal of Gastroenterology and Hepatology, 13(3), 285-290.

Bardella, M. T., Fraquelli, M., Quatrini, M., Molteni, N., Bianchi, P., & Conte, D. (2004). Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology, 22(3), 833-836.

Biagi, F., & Corazza, G. R. (2002). Mortality in celiac disease. Nature Reviews Gastroenterology and Hepatology, 7(3), 158-162.

Biagi, F., Campanella, J., Martucci, S., Pezzimenti, D., Ciclitira, P. J., Ellis, H. J., & Corazza, G. R. (2010). A milligram of gluten a day keeps the mucosal recovery away: A case report. Nutrition Reviews, 62(9), 360-363.

Calder, P. C. (2013). Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? British Journal of Clinical Pharmacology, 75(3), 645-662.

Caminero, A., Galipeau, H. J., McCarville, J. L., Johnston, C. W., Bernier, S. P., Russell, A. K., Jury, J., Herran, A. R., Casqueiro, J., Tye-Din, J. A., Surette, M. G., Magarvey, N. A., Schuppan, D., & Verdu, E. F. (2016). Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology, 151(4), 670-683.

Catassi, C., Elli, L., Bonaz, B., Bouma, G., Carroccio, A., Castillejo, G., Cellier, C., Cristofori, F., de Magistris, L., Dolinsek, J., Dieterich, W., Francavilla, R., Hadjivassiliou, M., Holtmeier, W., Körner, U., Leffler, D. A., Lundin, K. E., Mazzarella, G., Mulder, C. J., … Fasano, A. (2015). Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno experts’ criteria. Nutrients, 7(6), 4966-4977.

Coeffier, M., Miralles-Barrachina, O., Le Pessot, F., Lalaude, O., Daveau, M., Lavoinne, A., Lerebours, E., & Déchelotte, P. (2010). Influence of glutamine on cytokine production by human gut in vitro. Cytokine, 13(3), 148-154.

Cryan, J. F., O’Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., … Dinan, T. G. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877-2013.

Czerucka, D., Piche, T., & Rampal, P. (2007). Review article: Yeast as probiotics — Saccharomyces boulardii. Alimentary Pharmacology and Therapeutics, 26(6), 767-778.

Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46-56.

Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011). Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology, 36(3), 426-436.

Emilsson, L., Carlsson, R., James, S., Hambraeus, K., & Ludvigsson, J. F. (2015). The characterization and outcome of celiac disease in patients with heart failure: A prospective cohort study. BMC Gastroenterology, 15, 85.

Fasano, A. (2012). Leaky gut and autoimmune diseases. Clinical Reviews in Allergy and Immunology, 42(1), 71-78.

Fasano, A., & Catassi, C. (2012). Celiac disease. New England Journal of Medicine, 367(25), 2419-2426.

Francavilla, R., Piccolo, M., Francavilla, A., Polimeno, L., Semeraro, F., Cristofori, F., Castellaneta, S., Barone, M., Indrio, F., Verdu, E. F., & Catassi, C. (2012). Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms. Journal of Pediatric Gastroenterology and Nutrition, 53(6), 659-665.

Frustaci, A., Cuoco, L., Chimenti, C., Pieroni, M., Fioravanti, G., Gentiloni, N., Maseri, A., & Gasbarrini, G. (2002). Celiac disease associated with autoimmune myocarditis. Circulation, 105(22), 2611-2618.

Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N. N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., … Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446-450.

Hadjivassiliou, M., Boscolo, S., Davies-Jones, G. A., Grünewald, R. A., Not, T., Sanders, D. S., Simpson, J. E., Tongiorgi, E., Williamson, C. A., & Woodroofe, N. M. (2003). The humoral response in the pathogenesis of gluten ataxia. Neurology, 58(8), 1221-1226.

Hadjivassiliou, M., Sanders, D. S., Grünewald, R. A., Woodroofe, N., Boscolo, S., & Aeschlimann, D. (2010). Gluten sensitivity: From gut to brain. Lancet Neurology, 9(3), 318-330.

Haldeman, S., & Dagenais, S. (2008). A supermarket approach to the evidence-informed management of chronic low back pain. Spine Journal, 8(1), 1-7.

Husby, S., Koletzko, S., Korponay-Szabó, I., Kurppa, K., Mearin, M. L., Ribes-Koninckx, C., Shamir, R., Troncone, R., Auricchio, R., Castillejo, G., Christoph, C., Dolinsek, J., Gillett, P., Hauer, A., Heinonen, K., Hervieg, M., Kirchner, M., Lechtenberg, R., Mäki, M., … Werkstetter, K. (2020). European Society Pediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020. Journal of Pediatric Gastroenterology and Nutrition, 70(1), 141-156.

Hviid, A., Hansen, J. V., Frisch, M., & Melbye, M. (2021). Fecal microbiota transplantation for recurrent Clostridioides difficile: Systematic review and meta-analysis. Annals of Internal Medicine, 174(5), 687-695.

[Jimenez, A. (2024). Clinical observations and patient education resources. Personal Injury Doctor Group. https://personalinjurydoctorgroup.com/](https://personalinjurydoctorgroup.com/)

Junker, Y., Zeissig, S., Kim, S. J., Barisani, D., Wieser, H., Leffler, D. A., Zevallos, V., Libermann, T. A., Dillon, S., Freitag, T. L., Kelly, C. P., & Schuppan, D. (2012). Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. Journal of Experimental Medicine, 209(13), 2395-2408.

Kiela, P. R., & Ghishan, F. K. (2016). Physiology of intestinal absorption and secretion. Best Practice and Research Clinical Gastroenterology, 30(2), 145-159.

Kong, J., Zhang, Z., Musch, M. W., Ning, G., Sun, J., Hart, J., Bissonnette, M., & Li, Y. C. (2008). Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. American Journal of Physiology – Gastrointestinal and Liver Physiology, 294(1), G208-G216.

Leach, R. A. (2008). The chiropractic theories: A textbook of scientific research (4th ed.). Williams and Wilkins.

Leffler, D. A., Kelly, C. P., Abdallah, H. Z., Colatrella, A. M., Harris, L. A., Leon, F., Arterburn, L. A., Paterson, B. M., Lan, Z. H., & Murray, J. A. (2012). A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. American Journal of Gastroenterology, 107(10), 1554-1562.

Leffler, D. A., Schuppan, D., Pallav, K., Najarian, R., Goldsmith, J. D., Hansen, J., Kabbani, T., Dennis, M., & Kelly, C. P. (2013). Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut, 62(7), 996-1004.

Lubrano, E., Ciacci, C., Ames, P. R., Mazzacca, G., Oriente, P., & Scarpa, R. (1996). The arthritis of coeliac disease: Prevalence and pattern in 200 adult patients. British Journal of Rheumatology, 35(12), 1314-1318.

Lundin, K. E. A., & Wijmenga, C. (2015). Coeliac disease and autoimmune disease — genetic overlap and screening. Nature Reviews Gastroenterology and Hepatology, 12(9), 507-515.

Murray, J. A., Kelly, C. P., Green, P. H., Marcantonio, A., Wu, T. T., Mäki, M., & Collin, P. (2017). No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology, 152(4), 787-798.

Olmos, M., Antelo, M., Vázquez, H., Smecuol, E., Mauriño, E., & Bai, J. C. (2008). Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Digestive and Liver Disease, 40(1), 46-53.

Refsum, H., Smith, A. D., Ueland, P. M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., & Scott, J. M. (2004). Facts and recommendations about total homocysteine determinations: An expert opinion. Clinical Chemistry, 50(1), 3-32.

Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., & Murray, J. A. (2013). ACG clinical guidelines: Diagnosis and management of celiac disease. American Journal of Gastroenterology, 108(5), 656-676.

Rubio-Tapia, A., Kyle, R. A., Kaplan, E. L., Johnson, D. R., Page, W., Erdtmann, F., Brantner, T. L., Kim, W. R., Phelps, T. K., Lahr, B. D., Zinsmeister, A. R., Melton, L. J., & Murray, J. A. (2009). Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology, 137(1), 88-93.

Rubio-Tapia, A., Rahim, M. W., See, J. A., Lahr, B. D., Wu, T. T., & Murray, J. A. (2010). Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. American Journal of Gastroenterology, 105(6), 1412-1420.

Salmi, T. T. (2019). Dermatitis herpetiformis. Clinical and Experimental Dermatology, 44(7), 728-731.

Samsel, A., & Seneff, S. (2013). Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdisciplinary Toxicology, 6(4), 159-184.

Sapone, A., Bai, J. C., Ciacci, C., Dolinsek, J., Green, P. H., Hadjivassiliou, M., Kaukinen, K., Rostami, K., Sanders, D. S., Schumann, M., Ullrich, R., Villalta, D., Volta, U., Catassi, C., & Fasano, A. (2012). Spectrum of gluten-related disorders: Consensus on new nomenclature and classification. BMC Medicine, 10, 13.

Sárdy, M., Kárpáti, S., Merkl, B., Paulsson, M., & Smyth, N. (2002). Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. Journal of Experimental Medicine, 195(6), 747-757.

Sategna-Guidetti, C., Volta, U., Ciacci, C., Usai, P., Carlino, A., De Franceschi, L., Camera, A., Pelli, A., & Brossa, C. (2001). Prevalence of thyroid disorders in untreated adult celiac disease patients and effect of gluten withdrawal: An Italian multicenter study. American Journal of Gastroenterology, 96(3), 751-757.

Skodje, G. I., Sarna, V. K., Minelle, I. H., Rolfsen, K. L., Muir, J. G., Gibson, P. R., Veierød, M. B., Henriksen, C., & Lundin, K. E. A. (2018). Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology, 154(3), 529-539.

Sollid, L. M., Qiao, S. W., Anderson, R. P., Gianfrani, C., & Konig, F. (2012). Nomenclature and listing of celiac disease-relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics, 64(6), 455-460.

Sturniolo, G. C., Di Leo, V., Ferronato, A., D’Odorico, A., & D’Incà, R. (2001). Zinc supplementation tightens “leaky gut” in Crohn’s disease. Inflammatory Bowel Diseases, 7(2), 94-98.

Tracey, K. J. (2002). The inflammatory reflex. Nature, 420(6917), 853-859.

Turner, J. R. (2009). Intestinal mucosal barrier function in health and disease. Nature Reviews Immunology, 9(11), 799-809.

Tye-Din, J. A., Daveson, A. J. M., Ee, H. C., Spark, H., Jackson, M. L., Thompson, A. J. V., Goel, G., & Anderson, R. P. (2019). Phase 2 randomized controlled trial of Nexvax2, a peptide immunotherapy for celiac disease. JCI Insight, 4(22), e134955.

Ukil, A., Maity, S., Karmakar, S., Datta, N., Vedasiromoni, J. R., & Das, P. K. (2003). Curcumin, the major component of food flavor turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. British Journal of Pharmacology, 139(2), 209-218.

van der Hulst, R. R. W. J., van Kreel, B. K., von Meyenfeldt, M. F., Brummer, R. J. M., Arends, J. W., Deutz, N. E. P., & Soeters, P. B. (1993). Glutamine and the preservation of gut integrity. Lancet, 341(8857), 1363-1365.

van Hees, N. J. M., Van der Does, W., & Giltay, E. J. (2013). Coeliac disease, diet adherence and depressive symptoms. Journal of Psychosomatic Research, 74(2), 155-160.

Vanuytsel, T., van Wanrooy, S., Vanheel, H., Vanormelingen, C., Verschueren, S., Houben, E., Salim Rasoel, S., Tóth, J., Holvoet, L., Farré, R., Van Oudenhove, L., Boeckxstaens, G., Verbeke, K., & Tack, J. (2014). Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut, 63(8), 1293-1299.

Vojdani, A., & Tarash, I. (2013). Cross-reaction between gliadin and different food and tissue antigens. Food and Nutrition Sciences, 4(1), 20-32.

Wahab, P. J., Meijer, J. W., & Mulder, C. J. (2002). Histologic follow-up of people with celiac disease on a gluten-free diet: Slow and incomplete recovery. American Journal of Clinical Pathology, 118(3), 459-463.

Wüst, M., Mempel, M., & Ollert, M. (2009). Curcumin — an anti-inflammatory modulator of the NF-kB pathway? Der Hautarzt, 60(4), 280-288.

Content Creation Date: 2026-08-27

Author: Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933), Board-Certified in Internal Medicine

Practice: Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas

SEO Tags

celiac disease, non-celiac gluten sensitivity, NCGS, gluten intolerance, TTG IgA test, villous atrophy, intestinal permeability, leaky gut, zonulin, gliadin, tissue transglutaminase, dermatitis herpetiformis, gluten ataxia, peripheral neuropathy, gut microbiome, 5R gut healing protocol, functional medicine El Paso, integrative chiropractic care, Dr. Alex Jimenez DC, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, adaptive immune response, innate immune response, autoimmune disease, HLA-DQ2, HLA-DQ8, amylase trypsin inhibitors, fructans, FODMAP, mast cell degranulation, cytokine overload, molecular mimicry, cross-reactivity, gluten-free diet, gut healing, nutrient malabsorption, osteoporosis celiac, celiac neurological symptoms, celiac cardiovascular disease, multidisciplinary integrative care, personal injury chiropractic, threshold dynamics bucket model, gut-brain axis, vagus nerve gut immune function, L-glutamine gut repair, vitamin D intestinal healing, chiropractic autonomic nervous system, refractory celiac disease, larazotide acetate, latiglutenase, gluten challenge test, celiac serology, Marsh classification, butyrate microbiome, short-chain fatty acids immune regulation, adrenal exhaustion celiac, Hashimoto thyroiditis celiac, El Paso functional medicine, evidence-based integrative health